NCT01530256View on ClinicalTrials.gov

Exploratory Safety Study of ALD518 in Subjects With Steroid-refractory Acute Graft Versus Host Disease (GVHD)

PHASE1/PHASE2TerminatedINTERVENTIONAL
Enrollment

3

Participants

Timeline

Start Date

March 31, 2012

Primary Completion Date

March 31, 2013

Study Completion Date

March 31, 2013

Conditions
Acute GvHD
Interventions
BIOLOGICAL

ALD518

160 mg IV q 4 weeks for 4 doses

BIOLOGICAL

ALD518

320 mg IV q 4 weeks for 4 doses

BIOLOGICAL

ALD518

640 mg IV q 4 weeks for 2 doses

Trial Locations (5)

23298

Virginia Commonwealth University, Richmond

43210

The Ohio State University, Columbus

60153

Loyola Medical Center, Maywood

63110

Washington University, St Louis

91010

City of Hope, Duarte

Sponsors

Lead Sponsor

CSL Behring
All Listed Sponsors
lead

CSL Behring

INDUSTRY